Brazil to produce measles and rubella vaccine for poor countries

RIO DE JANEIRO Mon Oct 28, 2013 5:51pm IST

Brazil's Minister of Health Alexandre Padilha reacts after a conference for foreign doctors at the University of Brasilia August 26, 2013. REUTERS/Ueslei Marcelino

Brazil's Minister of Health Alexandre Padilha reacts after a conference for foreign doctors at the University of Brasilia August 26, 2013.

Credit: Reuters/Ueslei Marcelino

Related Topics

Stocks

   

RIO DE JANEIRO (Reuters) - Brazil´s top biomedical research and development center announced plans on Monday to produce a combined measles and rubella vaccine for developing countries, mainly in Africa.

The first Brazilian vaccine developed specifically for export will be made by Bio-Manguinhos, a unit of the Oswaldo Cruz Foundation (Fiocruz), in partnership with the Bill & Melinda Gates Foundation.

Brazilian health minister Alexandre Padilha announced the vaccine plan at a medical science conference that the Gates Foundation organized in Rio de Janeiro.

Brazil is following other leading emerging nations such as China and India in investing in biomedical technology to supply vaccines and medicines to developing countries at lower costs than those produced by pharmaceutical industries in developed nations.

Measles kills 158,000 people a year in the world, mostly children under the age of five. Rubella, a contagious viral disease with symptoms like mild measles, can cause serious consequences to pregnant women and their babies.

Bio-Manguinhos, which has a track record of making combined measles, mumps and rubella vaccines, will produce 30 million doses per year of the new measles/rubella vaccine to supply developing countries in Africa, Asia and Latin America.

This will increase the availability of a vaccine that today is produced by only one manufacturer, the Serum Institute of India Ltd.

The Gates Foundation said it would grant $1.1 million to support clinical trials and might contribute additional funds in subsequent phases of the project.

Bio-Manguinhos has been producing the combined measles, mumps and rubella vaccine since 2003 under a technology transfer agreement with GlaxoSmithKline Plc. This triple vaccine is used in Brazil´s immunization program, but was not adopted in many developing countries due to its cost and the limited epidemiological presence of mumps in a number of them.

The new measles/rubella vaccine is aimed at that group of nations and is expected to reach the market by 2017.

(Reporting by Anthony Boadle; Editing by Lisa Von Ahn)

FILED UNDER:

Ebola Crisis

REUTERS SHOWCASE

Ten Years On

Ten Years On

10 years on, tsunami warning stumbles at the "last mile".  Full Article 

Exit Polls

Exit Polls

BJP unlikely to form Jammu & Kashmir govt - polls.  Full Article 

Forceful Conversions

Forceful Conversions

BJP distances itself from religious conversions.  Full Article 

Hopeful Dhoni

Hopeful Dhoni

India's new vintage nearly ready, says Dhoni.  Full Article 

Photo

Fund Raising

Flipkart raises $700 million in fresh funding.   Full Article 

Reforms Push

Reforms Push

Modi may order insurance, coal reforms if vote delayed - officials.  Full Article 

Ali Hospitalized

Ali Hospitalized

Boxing great Muhammad Ali hospitalized with pneumonia.  Full Article 

Going International

Going International

Bollywood’s Priyanka Chopra sets sights on American TV.  Full Article 

India This Week

India This Week

Some of our best photos from this week.   Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device   Full Coverage